Dr. Steve Kanes, CMO and Dr. Jim Doherty, CRO at Sage Therapeutics discuss the three clinical trials, one major depressive disorder (MDD), one postpartum depression (PPD) and one Essential Tremor (ET) that the company was able to advance in spite of the pandemic. They talk about the learnings Sage is leveraging to overcome challenges that span all of brain health from MDD to emerging treatments that tackle executive function and development.
Steve Kanes, MD, CMO, is responsible for Sage’s clinical-stage programs and is the company’s primary liaison with the investigator community. His experience as a practicing psychiatrist helped him advance through increasing positions of responsibility at AstraZeneca Pharmaceuticals,culminating in his role as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division at the company. He is an adjunct assistant professor of psychiatry at the University of Pennsylvania School of Medicine and has authored or co-authored more than 30 peer-reviewed publications.He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry. Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.